Liquidia Stock Soars on Strong Yutrepia Sales

Liquidia (LQDA) stock surged 12.91% on Friday after the biotech company reported preliminary sales results for its commercialized product Yutrepia. The drug earned $148.3 million in net product sales in 2022, with $90.1 million in the fourth quarter alone. The company generated over $30 million in positive cash flow during Q4, boosting its cash and cash equivalents to $190.7 million. Liquidia aims to bolster clinical programs for Yutrepia and its investigational drug L606 across current and potential future indications.